U.S. regulators told Novartis to discontinue a print ad that allegedly overstated the benefits of irritable bowel drug Zelnorm and omitted important safety information. The ad did not mention the drug ...
The FDA has agreed to permit limited use of Novartis’ Zelnorm (tegaserod maleate) by some patients through a restricted access program, following the drug’s voluntary withdrawal over cardiovascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback